ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Neotigason®:Teva Pharma AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
D05BB02 - AcitretinATC-DDD Version 2016. Source: WHO
D - Dermatologicals

Most of the drugs in this group are preparations for topical use. Some few preparations for systemic use with clear dermatological applications, e.g. griseofulvin (antimycotic), retinoids (for treatment of acne) and psoralens and retinoids (for treatment of psoriasis) are classified in this group.

Only oral preparations in ATC group D are given DDDs. Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease. Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.

D05 - Antipsoriatics
 
D05B - Antipsoriatics for Systemic Use

This group comprises drugs for systemic use against psoriasis. Antineoplastic agents, sometimes used in severe psoriasis, are classified in group L - Antineoplastic and immunomodulating agents.
Agents with immunosuppressant properties indicated for treatment of psoriasis are classified in L04 - Immunosuppressants.

D05BB - Retinoids for Treatment Of Psoriasis

Retinoids for the treatment of acne are classified in D10BA.
Alitretinoin used for hand eczema is classified in D11A.

D05BB02 - Acitretin
StärkeAdm.RouteNote
35 mgO 
2019 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home